'Iron-saturated' lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy.

Show simple item record

dc.contributor.author Kanwar, JR en
dc.contributor.author Palmano, KP en
dc.contributor.author Sun, Xueying en
dc.contributor.author Kanwar, RK en
dc.contributor.author Gupta, R en
dc.contributor.author Haggarty, N en
dc.contributor.author Rowan, A en
dc.contributor.author Ram, S en
dc.contributor.author Krissansen, Geoffrey en
dc.coverage.spatial Australia en
dc.date.accessioned 2012-04-18T00:23:44Z en
dc.date.issued 2008 en
dc.identifier.citation Immunology and Cell Biology 86(3):277-288 2008 en
dc.identifier.issn 0818-9641 en
dc.identifier.uri http://hdl.handle.net/2292/17362 en
dc.description.abstract Bovine lactoferrin (bLf), an iron-containing natural defence protein found in bodily secretions, has been reported to inhibit carcinogenesis and the growth of tumours. Here, we investigated whether natural bLf and iron-saturated forms of bLf differ in their ability to augment cancer chemotherapy. bLf was supplemented into the diet of C57BL/6 mice that were subsequently challenged subcutaneously with tumour cells, and treated by chemotherapy. Chemotherapy eradicated large (0.6 cm diameter) EL-4 lymphomas in mice that had been fed iron-saturated bLf (here designated Lf(+)) for 6 weeks prior to chemotherapy, but surprisingly not in mice that were fed lesser iron-saturated forms of bLf, including apo-bLf (4% iron saturated), natural bLf (approximately 15% iron saturated) and 50% iron-saturated bLf. Lf(+)-fed mice bearing either EL-4, Lewis lung carcinoma or B16 melanoma tumours completely rejected their tumours within 3 weeks following a single injection of either paclitaxel, doxorubicin, epirubicin or fluorouracil, whereas mice fed the control diet were resistant to chemotherapy. Lf(+) had to be fed to mice for more than 2 weeks prior to chemotherapy to be wholly effective in eradicating tumours from all mice, suggesting that it acts as a competence factor. It significantly reduced tumour vascularity and blood flow, and increased antitumour cytotoxicity, tumour apoptosis and the infiltration of tumours by leukocytes. Lf(+) bound to the intestinal epithelium and was preferentially taken up within Peyer's patches. It increased the production of Th1 and Th2 cytokines within the intestine and tumour, including TNF, IFN-gamma, as well as nitric oxide that have been reported to sensitize tumours to chemotherapy. Importantly, it restored both red and white peripheral blood cell numbers depleted by chemotherapy, potentially fortifying the mice against cancer. In summary, bLf is a potent natural adjuvant and fortifying agent for augmenting cancer chemotherapy, but needs to be saturated with iron to be effective. en
dc.language eng en
dc.publisher Nature Publishing Group en
dc.relation.ispartofseries Immunology and Cell Biology en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/0818-9641/ en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.subject Adjuvants, Immunologic en
dc.subject Adjuvants, Pharmaceutic en
dc.subject Animals en
dc.subject Antineoplastic Combined Chemotherapy Protocols en
dc.subject Carcinoma, Lewis Lung en
dc.subject Cattle en
dc.subject Cytotoxicity, Immunologic en
dc.subject Dietary Supplements en
dc.subject Drug Resistance, Neoplasm en
dc.subject Immunohistochemistry en
dc.subject Iron en
dc.subject Lactoferrin en
dc.subject Lymphoma en
dc.subject Melanoma, Experimental en
dc.subject Mice en
dc.subject Mice, Inbred C57BL en
dc.subject Neoplasm Transplantation en
dc.subject Neovascularization, Pathologic en
dc.title 'Iron-saturated' lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy. en
dc.type Journal Article en
dc.identifier.doi 10.1038/sj.icb.7100163 en
pubs.issue 3 en
pubs.begin-page 277 en
pubs.volume 86 en
dc.rights.holder Copyright: Australasian Society for Immunology Inc. en
dc.identifier.pmid 18268518 en
pubs.end-page 288 en
dc.rights.accessrights http://purl.org/eprint/accessRights/RestrictedAccess en
pubs.subtype Article en
pubs.elements-id 115063 en
dc.identifier.pii 7100163 en
pubs.record-created-at-source-date 2012-04-18 en
pubs.dimensions-id 18268518 en


Files in this item

There are no files associated with this item.

Find Full text

This item appears in the following Collection(s)

Show simple item record

Share

Search ResearchSpace


Browse

Statistics